english.prescrire.org > Spotlight > Archives : 2020 > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2020 : 1 | 30 | 60

In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

FREE DOWNLOADIn patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality or cardiovascular mortality.
Full text available for free download.

Summary

  • In a randomised, placebo-controlled trial including about 10 000 patients with type 2 diabetes and a mean HbA1c of 7.3% at enrolment, addition of dulaglutide to their usual hypoglycaemic therapy did not reduce all-cause or cardiovascular mortality after a follow-up of about 5 years.
     
  • The increased risk of acute pancreatitis and pancreatic or thyroid cancer must be taken into account, as with any GLP-1 receptor agonist.

Full text available for free download.

 ©Prescrire 1 May 2020

"Dulaglutide and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality" Prescrire Int 2020; 29 (215): 134. (Pdf, free).

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free

See also:

Dulaglutide weekly
in type 2 diabetes.
Cardiovascular reactions
should be better documented
Prescrire Int 2016;
25 (175): 236-237.
Pdf, subscribers only

Diabetes and liraglutide.
Very tenuous results
from the Leader trial
Prescrire Int 2017;
26 (186): 246-247.
Pdf, subscribers only

Glucose-lowering treatment
of type 2 diabetes. Part II -
Glucose-lowering options
after metformin: a difficult choice
based largely on adverse effects
Prescrire Int 2015;
24 (160): 130-135.
Pdf, subscribers only